AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22451121 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor size ≤14 mm
Number of subjects: 75
Study 22451121 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral tumor
Number of subjects: 75
Study 20406791 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention group
Number of subjects: 990
Study 20406791 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention group
Number of subjects: 990
Study 20406791 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 990
Study 17701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of CD3, CD4, CD8, Helper/Suppressor ratio, and CD19 subpopulations of lymphocytes in patients with osteomyelitis.
Number of subjects: 145
Study 17701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of lymphocyte subpopulations in patients with osteosarcomas, Ewing sarcomas, giant cell tumours, chondrosarcomas, and other tumours.
Number of subjects: 145
Study 17701188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut off point values for diagnosing osteomyelitis: CD3 2420, CD4 1400, CD8 873, CD19 550.
Number of subjects: 145
Study 15917066 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) cervical screening brief advice
Number of subjects: 17008
Study 12687805 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sites (AL + L + PL CST, 134 patients)
Number of subjects: 158
Study 12687805 — intervention group
Group type: COMPARATOR
Intervention: Septal sites (A + MCV CST, 24 patients)
Number of subjects: 158
Study 10426754 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised controlled trials evaluating treatment of existing conditions
Number of subjects: 0
Study 10426754 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised studies
Number of subjects: 0
Study 10426754 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study 7724096 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol management (bupivacaine, metoclopramide, scopolamine, ketorolac, gastric suctioning)
Number of subjects: 71
Study 7724096 — intervention group
Group type: COMPARATOR
Intervention: Control (nontreatment group)
Number of subjects: 71
Study 7724096 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol management
Number of subjects: 71
Study 7724096 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 2294762 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (interviewed 7 days after vaccination)
Number of subjects: 650
Study 7352688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (5 mg)
Number of subjects: 33
Study 7352688 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (5 mg)
Number of subjects: 33
Study 6084061 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus exposure in Introverts
Number of subjects: 0
Study 6084061 — intervention group
Group type: COMPARATOR
Intervention: Rhinovirus exposure in Extroverts
Number of subjects: 0
Study 6084061 — intervention group
Group type: COMPARATOR
Intervention: Influenza virus exposure
Number of subjects: 0
Study 6084061 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoneurotic symptoms (self-report inventory)
Number of subjects: 0
Study 6084061 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessional Symptoms scale
Number of subjects: 0
Study 6084061 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 0
Study 29931798 — intervention group
Group type: EXPERIMENTAL
Intervention: Forum plus modules treatment group (Group 2)
Number of subjects: 304
Study 29931798 — intervention group
Group type: EXPERIMENTAL
Intervention: Forum, modules, and tools treatment group (Group 3)
Number of subjects: 304
Study 29846283 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT) - percutaneous estradiol [E2] gel [0.1%, 2 mg/d] and oral micronized progesterone [MP4] [100 mg/d]
Number of subjects: 37
Study 29846283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 26867793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (CFPM)
Number of subjects: 45
Study 26867793 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (MEPM)
Number of subjects: 45
Study 24421266 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Poly® (APP) ingestion
Number of subjects: 0
Study 24421266 — intervention group
Group type: COMPARATOR
Intervention: RES (monomeric polyphenol) ingestion
Number of subjects: 0
Study 24421266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of APP before injection of polyI:C
Number of subjects: 0
Study 24421266 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCs from two different sources
Number of subjects: 0
Study 24421266 — intervention group
Group type: COMPARATOR
Intervention: Monomeric form of procyanidin
Number of subjects: 0
Study 22797003 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine supplementation (BA, 2 × 800 mg tablets, 3 times daily)
Number of subjects: 50
Study 22797003 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, 2 × 800 mg maltodextrin tablets, 3 times daily)
Number of subjects: 50
Study 20510808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day intensive surgical skills boot camp
Number of subjects: 28
Study 20510808 — intervention group
Group type: COMPARATOR
Intervention: Control group (no boot camp)
Number of subjects: 28
Study 17359403 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg(‐1) midazolam (group H)
Number of subjects: 115
Study 17359403 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg.kg(‐1) midazolam (group L)
Number of subjects: 115
Study 17359403 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of midazolam
Number of subjects: 115
Study 15589564 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily
Number of subjects: 0
Study 15589564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12403802 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 nurse-initiated calls
Number of subjects: 181
Study 12403802 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 nurse-initiated calls plus 10 motivational calls programmed through an automated phone calling system
Number of subjects: 181
Study 12403802 — intervention group
Group type: COMPARATOR
Intervention: No program-initiated phone contacts
Number of subjects: 181
Study 10207574 — intervention group
Group type: EXPERIMENTAL
Intervention: Body-rocking in college students
Number of subjects: 0
Study 10207574 — intervention group
Group type: COMPARATOR
Intervention: Body-rocking in individuals with mental retardation
Number of subjects: 0
Study 10207574 — intervention group
Group type: COMPARATOR
Intervention: Comparison of body-rocking characteristics
Number of subjects: 0
Study 7613796 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (alpha 1-adrenergic blocker)
Number of subjects: 11
Study 7613796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2795991 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenacetin
Number of subjects: 8
Study 2795991 — intervention group
Group type: COMPARATOR
Intervention: Phenacetin, aspirin and caffeine
Number of subjects: 8
Study 150142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-Nerisone cream (Diflucortolone valerate + Chlorquinaldol)
Number of subjects: 343
Study 150142 — intervention group
Group type: COMPARATOR
Intervention: Control preparation (Betamethasone valerate + Gentamicin + Tolnaftate + Clioquinol)
Number of subjects: 343
Study 31152865 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 176
Study 31152865 — intervention group
Group type: COMPARATOR
Intervention: Email contact
Number of subjects: 176
Study 27378787 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting physical activity (13 individual sessions delivered by a coach trained in motivational interviewing, beginning two months before and ending six months after discharge)
Number of subjects: 39
Study 27378787 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting physical activity
Number of subjects: 39
Study 25274197 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) and exercise
Number of subjects: 0
Study 25274197 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (placebo HILT) and exercise
Number of subjects: 0
Study 23602289 — intervention group
Group type: COMPARATOR
Intervention: Statins
Number of subjects: 5628
Study 21109517 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment regimens for ANCA-associated vasculitis
Number of subjects: 535
Study 21109517 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched general population
Number of subjects: 535
Study 19928483 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance physical activity interventions
Number of subjects: 22
Study 19928483 — intervention group
Group type: EXPERIMENTAL
Intervention: Print medium plus telephone contact
Number of subjects: 22
Study 19928483 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study 17699491 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxadrop (3.6 g of granulate each day)
Number of subjects: 20
Study 17699491 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.6 g of granulate each day)
Number of subjects: 20
Study 15633852 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 program components of a multifaceted preventive intervention (6-week summer program, biweekly family program, home visitation family support program)
Number of subjects: 124
Study 15633852 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week summer program
Number of subjects: 124
Study 15633852 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly family program
Number of subjects: 124
Study 15633852 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation family support program
Number of subjects: 124
Study 10867675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat principle
Number of subjects: 0
Study 10867675 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual of the regression of actual treatment indicator on randomization arm indicator
Number of subjects: 0
Study 9045214 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made pacemaker incorporating an accelerometer
Number of subjects: 49
Study 1532350 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural sufentanil with epinephrine
Number of subjects: 40
Study 1532350 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline and epinephrine)
Number of subjects: 40
Study 3986086 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.2 mg)
Number of subjects: 9
Study 3986086 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa (750 mg)
Number of subjects: 9
Study 29763353 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri probiotic lozenges (n = 90)
Number of subjects: 178
Study 29763353 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (n = 88)
Number of subjects: 178
Study 28744807 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tranexamic acid (5 mg/kg bolus loading dose and 1 mg/kg continuous infusion)
Number of subjects: 72
Study 28744807 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (10 mg/kg bolus loading dose and 2 mg/kg continuous infusion)
Number of subjects: 72
Study 28744807 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled group
Number of subjects: 72
Study 26432315 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-borne maxillary hyrax expander (TBME)
Number of subjects: 20
Study 26432315 — intervention group
Group type: COMPARATOR
Intervention: Bone-borne maxillary hyrax expander (BBME)
Number of subjects: 20
Study 23124782 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 10 g/d
Number of subjects: 154
Study 23124782 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 12.5 g/d
Number of subjects: 154
Study 23124782 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 5.0 g/d
Number of subjects: 154
Study 23124782 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 7.5 g/d
Number of subjects: 154
Study 23124782 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer-HCl 4.8 g/d
Number of subjects: 154
Study 23124782 — intervention group
Group type: EXPERIMENTAL
Intervention: PA21 (pooled)
Number of subjects: 154
Study 23124782 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer-HCl (pooled)
Number of subjects: 154
Study 21486726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as per Chinese textbook standards
Number of subjects: 24
Study 21486726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as per expert's personally preferred style
Number of subjects: 24
Study 21486726 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture as per local styles of acupuncture
Number of subjects: 24
Study 18552237 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GDP solution
Number of subjects: 56
Study 18552237 — intervention group
Group type: COMPARATOR
Intervention: High-GDP (standard) solution
Number of subjects: 56
Study 17003737 — intervention group
Group type: EXPERIMENTAL
Intervention: SP/AP ratio
Number of subjects: 40
Study 17003737 — intervention group
Group type: EXPERIMENTAL
Intervention: SP-AP waveform width
Number of subjects: 40
Study 17003737 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean product of SP-AP waveform width and SP/AP
Number of subjects: 40
Study 17003737 — intervention group
Group type: EXPERIMENTAL
Intervention: AP latency difference
Number of subjects: 40
Study 17003737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity for SP-AP waveform width
Number of subjects: 40
Study 17003737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity for SP/AP
Number of subjects: 40
Study 17003737 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity for AP latency difference
Number of subjects: 40
Study 12657387 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparoscopic cholecystectomy (MLC)
Number of subjects: 69
Study 12657387 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 69
Study 12657387 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MLC and CLC
Number of subjects: 69
Study 10731543 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose nafarelin treatment (200 microgram b.i.d.) for 24 weeks (n = 7)
Number of subjects: 15
Study 10731543 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose nafarelin treatment (200 microgram daily) for 20 weeks after 4 weeks of full-dose nafarelin (n = 8)
Number of subjects: 15
Study 8736459 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol monotherapy (5-10 mg daily for 6 months)
Number of subjects: 47
Study 8736459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with betaxolol and nitrendipine (10-20 mg once daily from month 7 to 12)
Number of subjects: 47
Study 8736459 — intervention group
Group type: COMPARATOR
Intervention: Control group (Betaxolol only during Phase II)
Number of subjects: 47
Study 1342802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooling specimens using Dorfman's two-stage model with 22 individual serum samples in each of 46 pools.
Number of subjects: 3036
Study 1342802 — intervention group
Group type: COMPARATOR
Intervention: Control group with no positive samples in the third set of 1012 sera.
Number of subjects: 3036
Study 4059903 — intervention group
Group type: EXPERIMENTAL
Intervention: fenbufen
Number of subjects: 50
Study 4059903 — intervention group
Group type: EXPERIMENTAL
Intervention: feprazone
Number of subjects: 50
Study 4059903 — intervention group
Group type: EXPERIMENTAL
Intervention: benoxaprofen
Number of subjects: 50
Study 4059903 — intervention group
Group type: EXPERIMENTAL
Intervention: flurbiprofen
Number of subjects: 50
Study 4059903 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoprofen
Number of subjects: 50
Study 30758247 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application
Number of subjects: 100
Study 30758247 — intervention group
Group type: COMPARATOR
Intervention: Pedometer
Number of subjects: 100
Study 30518059 — intervention group
Group type: EXPERIMENTAL
Intervention: Peas
Number of subjects: 11
Study 30518059 — intervention group
Group type: COMPARATOR
Intervention: Couscous (control food)
Number of subjects: 11
Study 26739038 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplementary feeding based on MUAC of 115-124 mm
Number of subjects: 0
Study 26739038 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 24364795 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic cognitive behavioral intervention package (OCB) - 8 sessions plus group therapy
Number of subjects: 185
Study 24364795 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 185
Study 23230755 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich gel (APG)
Number of subjects: 86
Study 23230755 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 86
Study 20722793 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plants (e.g., Ferula hermonis, Angelica sinensis, Ginkgo biloba)
Number of subjects: 0
Study 20722793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa, Trifolium pratense, Vitex agnus‐castus
Number of subjects: 0
Study 20722793 — intervention group
Group type: EXPERIMENTAL
Intervention: Humulus lupulus, Tribulus terrestris
Number of subjects: 0
Study 20722793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lepidium meyenii
Number of subjects: 0
Study 20722793 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plants
Number of subjects: 0
Study 18418336 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) cycling
Number of subjects: 20
Study 18418336 — intervention group
Group type: COMPARATOR
Intervention: Standard Rehabilitation (SR)
Number of subjects: 20
Study 16185033 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser scanning technique measuring time-resolved autofluorescence
Number of subjects: 47
Study 16185033 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of confocal laser scanning technique with aperture diaphragm division
Number of subjects: 47
Study 12813117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy for depression (weekly 90-minute sessions for 16 weeks)
Number of subjects: 284
Study 12813117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 284
Study 12813117 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interpersonal psychotherapy for depression
Number of subjects: 284
Study 11093597 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan diet
Number of subjects: 18
Study 7956409 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefonicid daily intravenously started at chest tube insertion and stopped within 24 h of removal
Number of subjects: 119
Study 7956409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 7956409 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefonicid daily intravenously
Number of subjects: 119
Study 7956409 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with infectious complications
Number of subjects: 119
Study 2885355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg
Number of subjects: 10
Study 2885355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 10
Study 2885355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 10
Study 2885355 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine 25 mg
Number of subjects: 10
Study 2885355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31611105 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (DCBs)
Number of subjects: 44
Study 31611105 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloons (CBs)
Number of subjects: 44
Study 29877995 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based calculator tool for communicating estimates of personalized treatment outcomes
Number of subjects: 1324
Study 27595181 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute Integrity stents
Number of subjects: 817
Study 27595181 — intervention group
Group type: COMPARATOR
Intervention: Promus Element stents
Number of subjects: 817
Study 27061810 — intervention group
Group type: EXPERIMENTAL
Intervention: TEGAFIRI +/‐ bevacizumab
Number of subjects: 71
Study 27061810 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI +/‐ bevacizumab
Number of subjects: 71
Study 22339214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 60
Study 22339214 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 60
Study 21879639 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific psychosocial intervention (G1, 8 sessions)
Number of subjects: 66
Study 21879639 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group (G2, 8 sessions)
Number of subjects: 66
Study 21879639 — intervention group
Group type: COMPARATOR
Intervention: Control group (G3)
Number of subjects: 66
Study 18673417 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy (five times daily using inter-positioning tongue spatulas, adding a new spatula every 5-10 days)
Number of subjects: 54
Study 18673417 — intervention group
Group type: COMPARATOR
Intervention: Local injection of hyaluronidase with steroids
Number of subjects: 54
Study 18673417 — intervention group
Group type: COMPARATOR
Intervention: No active treatment
Number of subjects: 54
Study 16996517 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-day training programme
Number of subjects: 49
Study 15523448 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered hypertonic saline
Number of subjects: 0
Study 15523448 — intervention group
Group type: COMPARATOR
Intervention: Buffered normal saline
Number of subjects: 0
Study 11340797 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific speech and language therapy (SLT) including a portable metronome brooch to cue swallowing
Number of subjects: 0
Study 11340797 — intervention group
Group type: EXPERIMENTAL
Intervention: Injections of botulinum toxin into both parotid glands
Number of subjects: 0